Introduction
Angiogenesis, the process of new blood vessel growth from pre-existing capillaries, is involved in physiological and pathological processes such as embryonic development, wound healing, reproductive cycles, diabetic retinopathy, chronic inflammation, tumor growth and metastasis (1) . Thus, suppression of abnormal angiogenesis may provide therapeutic strategies for the treatment of angiogenesis-dependent disorders. Vascular endothelial growth factor (VEGF), which has been shown to be a major factor secreted by tumor cells, plays an important role in the expansion of the microvascular network needed to supply oxygen and nutrients for the rapid growth of tumor masses (2) . VEGF was initially defined, characterized and purified for its ability to induce vascular leak and permeability as well as for its ability to promote vascular endothelial cell proliferation and migration and to act as a crucial survival factor for endothelial cells (EC) (3) . It is a specific EC mitogen that binds with high affinity to the EC receptors VEGFR-1 (Flt-1) and VEGFR-2 (Flk-1/KDR), the latter being responsible for most of the mitogenic and chemotactic effects of VEGF (4) . Therefore, the development of antiangiogenesis therapies directed against the VEGF-VEGFR-2 kinase axis has become an important approach for the treatment of angiogenesisdependent diseases (5) .
There is increasing evidence that polyphenols found in natural products may interfere with several processes involved in cancer and metastasis. In this respect, we have shown that several green tea catechins inhibit matrix metalloproteinase (MMP)-dependent activities in vitro (6) as well as tumor cell migration and invasion (7, 8) , and that these molecules are also potent inhibitors of in vitro angiogenesis (9, 10) , operating through inhibition of VEGF receptors (9) . Furthermore, we have reported recently that ellagic acid, a polyphenol present in fruits and nuts, inhibits both VEGF and PDGF receptors (11) . Among polyphenols, the anthocyanidins and their glycosylated forms (anthocyanins) appear to possess potentially beneficial effects against various diseases (12) . These phenolic compounds are widely found in many berries, red grapes, purple sweet potatoes, red cabbages, and other pigmented foods, plants and vegetables (13) . While the strong antioxidant potential of these molecules is well characterized (12) , information about the antitumor and the antiangiogenic activities of anthocyanidins remains largely unknown. In the present study, we investigated whether anthocyanidins (cyanidin (Cy), delphinidin (Dp), malvidin (Mv), pelargonidin (Pg), peonidin (Pn), petunidin, (Pt)) and a glycosylated form of delphinidin [delphinidin 3-O-beta-glucopyranoside (Dp 3-glu)] modulate angiogenesis in both in vitro and in vivo models. We present evidence that delphinidin acts as a potent inhibitor of both VEGFR-2 activities and of phosphorylation of the p42/44 mitogen-activated protein (MAP) kinase pathway (also known as ERK-1/2, extracellular-signal-regulated kinase 1 and 2), leading to an inhibition of VEGF-induced EC migration as well as to an inhibition of the morphogenic differentiation of EC into capillary-like structures in vitro. Moreover, the compound markedly inhibited basic fibroblast growth factor (bFGF)-induced new blood vessel formation in in vivo Matrigel plug assays. All these data suggest that delphinidin exerts antiangiogenic effects via its inhibitory effect on VEGFR-2 activity.
Cell culture
Human umbilical vein endothelial cells (HUVECs) were purchased from Clonetics (San Diego, CA) and maintained in EC basal medium-2 (EBM-2) supplemented with EGM-2 Mv growth factor mixture (Clonetics). The cells were cultured at 37 C under a humidified 95%/5% (v/v) mixture of air and CO 2 . For experimental purposes, cells were plated in 100 mm plastic dishes at 5000 cells/cm 2 and were grown to confluence before overnight serum starvation without supplements. Cells were treated with vehicle or with anthocyanidins diluted in 100% EtOH, and stimulated with VEGF.
Matrigel endothelial cell tube formation assays Matrigel (12.5 mg/ml) was thawed at 4 C, and 50 ml were quickly added to each well of a 96-well plate and allowed to solidify for 10 min at 37 C. The wells were then incubated for 6 h at 37 C with HUVEC (20 000 cells/well), which had previously been treated for 18 h with the indicated concentrations of anthocyanidins. The formation of capillary-like structures was examined microscopically and photographs (50Â) were taken using a Retiga 1300 camera and a Zeiss Axiovert S100 microscope. The extent to which capillary-like structures formed in the gel was quantified by analysis of digitized images to determine the thread length of the capillary-like network, using a commercially available image analysis program (Northern Eclipse, Mississauga, ON, Canada).
Capillary tube formation by EC in fibrin gels
HUVECs were embedded within fibrin gels at a concentration of 2.5 Â 10 5 cells/ml by the following technique. 250 ml of 2.5 mg/ml human fibrinogen solution (made in serum-free medium) was placed into a tube and human thrombin (0.5 U/ml) was added to the fibrinogen. This was quickly pipetted into the wells of 24-well plates (covering the entire surface of the wells) and allowed to clot at 37 C for 30 min. One milliliter aliquots of EC suspended in serum-free EC basal medium were seeded onto each fibrin gel. After 24 h, cells had spread to form a confluent monolayer. Cells were then pretreated with vehicle or with delphinidin (25 mM) for 1 h at 37 C. The same procedure was used to generate a second fibrin gel overlying the apical surface of the cells. This fibrin gel was allowed to polymerize for 10 min at 37 C and then, after the pretreatment of cells, 1 ml aliquots of fresh serum-free EC basal medium, supplemented with VEGF (75 ng/ml) and containing (or lacking) delphinidin (25 mM), were added to each well. After 6 h, the cultures were photographed (100Â).
Assessment of cell viability
Cell viability was determined by the trypan blue exclusion assay. Briefly, cells were treated with 25 mM delphinidin and incubated in a humidified atmosphere of 5% CO 2 in air at 37 C in EBM-2 medium for 18 h. After detaching with trypsin-EDTA, an equal volume of 0.4% trypan blue reagent (Gibco BRL, Burlington, ON, Canada) was added to the cell suspension and the proportions of viable cells were evaluated under the field microscope. About 100 cells were counted and cells stained dark blue were not considered viable.
Fluorimetric caspase 3 assay
Cells were grown to $85% confluence and treated for 18 h with delphinidin (25 mM) or with a well-characterized inducer of EC apoptosis, staurosporine (10 nM), as a positive control. Cells were collected, washed in cold phosphatebuffered saline (PBS) and lysed in Apo-alert lysis buffer (Clontech, Palo Alto, CA) for 20 min at 4 C. The lysates were clarified by centrifugation at 16 000 g for 20 min and caspase 3 activity was determined as described previously (14) using DEVD-AFC as the substrate.
Immunoprecipitation and immunoblotting procedures After treatment with VEGF (100 ng/ml) as described previously (15) , cells were washed once with ice-cold PBS (pH 7.4) containing 1 mM Na 3 VO 4 and were incubated in the same medium for 1 h at 4 C. The cells were solubilized on ice in lysis buffer [150 mM NaCl, 10 mM Tris-HCl (pH 7.4), 1 mM EDTA, 1 mM EGTA, 0.5% (v/v) Nonidet P-40 and 1% (v/v) Triton X-100] containing 1 mM Na 3 VO 4 . Lysates were clarified by centrifugation at 10 000 g for 10 min, and the resulting supernatants were used to immunoprecipitate VEGFR-2 overnight with 1 mg/ml of antibody at 4 C followed by the addition of protein A-(rabbit primary antibody) Sepharose beads at 4 C for 2 h, as described previously (11) . Non-specifically bound proteins were removed by washing the beads three times with lysis buffer and once with PBS containing 1 mM Na 3 VO 4 . The proteins were extracted with 2-fold concentrated Laemmli sample buffer, boiled 4 min, and resolved by SDS-PAGE (7.5% gel). The proteins were transferred onto polyvinylidene difluoride (PVDF) membranes, blocked overnight at 4 C in Tris-buffered saline/Tween-20 [147 mM NaCl, 20 mM Tris-HCl (pH 7.5) and 0.1% Tween-20] containing 2% (w/v) bovine serum albumin (BSA), and probed with primary antibodies (PY99 or VEGFR-2) for 2 h at room temperature. Immunoreactive bands were revealed after a 1 h incubation with HRP-conjugated anti-mouse IgG, and the signals were visualized by enhanced chemiluminescence. The immunoreactive bands were quantified by scanning densitometry (Molecular Dynamics, Sunnyvale, CA).
Analysis of ERK-1/2 phosphorylation
Cells treated with vehicle or with anthocyanidins for 18 h were stimulated with 50 ng/ml VEGF for 10 min and then washed, incubated in PBS containing 1 mM of each NaF and Na 3 VO 4 , and solubilized on ice in lysis buffer. Lysates (20 mg) were solubilized in Laemmli sample buffer, boiled for 4 min, separated on 10% SDS-PAGE and analyzed by western blotting.
Migration assays
Chemotactic motility of HUVEC was assayed using Transwells (8 mm pore size; Costar, Cambridge, MA) as described previously (11) . Briefly, HUVECs were seeded at a density of 1.0 Â 10 6 cells/ml in serum-free medium and were allowed to adhere to gelatin-coated transwells for 30 min. Then, cells were incubated for 2 h with various concentrations of delphinidin before the addition of VEGF (50 ng/ml) to the lower chamber as a chemoattractant and placed at 37 C in 5% CO 2 /95% air for another 3 h. Cells that had migrated to the lower surface of the filters were fixed with 10% formalin phosphate and stained with 0.1% crystal violet/20% (v/v) methanol. The migration was quantitated using computer-assisted imaging and data are expressed as the average density of migrated cells per four fields (magnification Â50).
In vivo Matrigel plug assay
The Matrigel plug assay is based on the method of Passaniti (16), with modifications. Briefly, Crl:CD-1 Ò -nuBR nude mice (Charles River Laboratories, St Constant, Qc, Canada) were treated by injection subcutaneously (s.c.) into the ventral midline region of the right flank with 0.5 ml of phenol red-free Matrigel (BD Bioscience, Mississauga, ON, Canada) containing delphinidin (300 mM), bFGF (250 ng/ml) and heparin (0.0025 U/ml) to allow the formation of solid gel plugs. Matrigel containing ethanol alone was injected into some animals to serve as baseline controls. After 7 days, the mice were killed and the Matrigel implant harvested, washed with PBS, immediately frozen and lyophilized overnight. After resolubilization in 0.1% Triton X-100, the concentration of hemoglobin was determined directly by absorbance at 405 nm and compared with a standard curve of purified hemoglobin (Sigma-Aldrich, Oakville, ON, Canada), as described previously (17) .
Statistical analysis
The data are presented as mean AE SEM and statistical comparisons between groups were performed using one-way ANOVA followed by Student's t-test.
Results

Delphinidin inhibits tube formation of endothelial cells
The effect of six kinds of anthocyanidins (Cy, Dp, Mv, Pg, Pn and Pt) (Table I ) and of a glycosylated form, Dp 3-glu, on the morphological differentiation of EC was investigated using a 2D model with Matrigel, a laminin-rich reconstituted basement membrane matrix. Treatment of HUVEC with 15 mM of the compounds for 18 h, before adhesion to Matrigel, S.Lamy et al.
affected tube formation compared to the control ( Figure 1A) ; this process was nearly abolished by delphinidin ($76% inhibition) ( Figure 1B ). As shown in Figure 1C , delphinidin abrogated the width and the length of endothelial tubular structures in a concentration-dependent manner (IC 50 ¼ 9.5 mM; Figure 1D ). This process was completely abolished by delphinidin at 25 mM. These results show that delphinidin was the anthocyanidin most effective at inhibiting EC differentiation.
Delphinidin inhibits VEGF-induced tube formation in 3D fibrin gels
There is now considerable evidence that 3D cell models represent attractive systems for closely mimicking the in vivo cellular microenvironment (18) . Growth of EC within fibrin gels is a suitable model for studying angiogenesis (19) , as fibrin is a common component of the extracellular matrix at sites of wounding, chronic inflammation and tumor stroma (20) . When VEGF was added to the HUVEC embedded in 3D fibrin gels, VEGF rapidly led to the formation of elongated and robust tube-like structures, compared to the control. Using this model, we observed that delphinidin also potently inhibited VEGF-induced capillary-like structure formation by HUVEC (Figure 2 ).
The antiangiogenic activity of delphinidin is not related to cell death In order to verify whether the inhibitory effect of 25 mM delphinidin was due to cytotoxicity, we measured HUVEC viability by trypan blue exclusion and caspase 3 activity. Induction of caspase 3 was used to monitor potential apoptotic actions of delphinidin in EC, based on the well-described role of this executioner caspase in apoptosis (21) . Figure 3A shows that delphinidin did not induce significant cell death compared to control cells after 18 h of treatment. Furthermore, no caspase 3 activity was detected in cells treated with delphinidin, unlike cells treated with staurosporine, an apoptotic inducer (Figure 3B ), confirming the specific antiangiogenic effect of delphinidin on EC tube formation.
Delphinidin inhibits VEGF-induced tyrosine phosphorylation of VEGFR-2
To better understand the inhibitory action of delphinidin on the induction of in vitro angiogenesis, we examined its effect on the function of VEGF. Since VEGF has been shown to be the central positive regulator of the early growth of neovessels (22) , and inhibition of VEGFR-2 activity limits the ability of most tumors to stimulate the formation of blood vessels (23), we examined whether delphinidin could have an effect on VEGF-induced tyrosine phosphorylation of VEGFR-2. Quiescent HUVECs were incubated for 18 h in serum-free medium in the presence or in the absence of 25 mM delphinidin or Dp 3-glu. The medium was then replaced with fresh serum-free medium without delphinidin and the cells were stimulated with 100 ng/ml of recombinant VEGF for 1 min. The phosphorylation state of the VEGFR-2 was assessed by immunoprecipitation of the receptor followed by Tyr(P) immunodetection. Under these experimental conditions, we observed a complete inhibition of VEGF-induced phosphorylation of VEGFR-2 by delphinidin, whereas Dp 3-glu was less potent, confirming that delphinidin is the most potent anthocyanidin inhibitor ( Figure 4A , top panel). Blotting of membranes with an antibody directed against VEGFR-2 showed that delphinidin did not affect the amount of VEGFR-2 in the immunoprecipitate ( Figure 4A, bottom panel) . Interestingly, the tyrosine phosphorylation of VEGFR-2 was rapidly inhibited by delphinidin after as little as 15 min and this inhibitory effect gradually increased at longer incubation times ( Figure 4B ). The fact that the inhibition by delphinidin was already complete at 25 mM for 18 h prompted us to more precisely examine the effect of lower concentrations of this molecule on tyrosine phosphorylation of VEGFR-2. As shown in Figure 4C , delphinidin caused a dose-dependent inhibition of VEGF-induced tyrosine phosphorylation of VEGFR-2 with an IC 50 of 2 mM. Overall, these results strongly support the concept that delphinidin interferes with the activity of VEGFR-2 at the EC level.
Delphinidin inhibits VEGF-induced ERK phosphorylation
Following VEGF-induced autophosphorylation of VEGFR-2, the receptor induces activation and/or phosphorylation of several substrates such as ERK-1/2 (4,24). As shown in Figure 5A (top panel), VEGF caused a marked increase in the tyrosine phosphorylation state of ERK-1/2 in untreated HUVEC. The increase in tyrosine-phosphorylated ERK-1/2 was completely inhibited by delphinidin at 25 mM compared to Dp 3-glu, which had no effect ( Figure 5A, top panel) . The total amount of ERK-1/2 was unaffected by these treatments ( Figure 5A , bottom panel). As shown in Figure 5B , delphinidin significantly inhibited VEGF-induced phosphorylation of ERK-1/2 in a dose-dependent manner, achieving a half maximal effect at 11.8 mM. These results demonstrate that the inhibitory effect of delphinidin on VEGFR-2 tyrosine phosphorylation alters the signaling cascade triggered by VEGF.
Delphinidin inhibits VEGF-induced migration of endothelial cells
Since migration of EC represents a critical step in angiogenesis, allowing cells to disseminate from pre-existing vessels and to form new vessels, the effect of delphinidin on migration was also investigated. We studied the effect of delphinidin on 
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HUVEC migration only after VEGF stimulation since, under control conditions, HUVEC migration is very low (data not shown). HUVECs were allowed to adhere to gelatin-coated transwells and were incubated for 2 h with different concentrations of delphinidin before the addition of VEGF (50 ng/ml) to the lower chamber. Under these conditions, delphinidin inhibited VEGF-induced migration of HUVEC in a dosedependent manner ( Figure 6 ). Overall these results demonstrate that delphinidin has the ability to block VEGF-induced in vitro angiogenesis.
Delphinidin inhibits bFGF-induced angiogenesis in vivo
In order to extend the observations made in vitro and to study the efficacy of delphinidin in vivo, an established in vivo angiogenesis model, the mouse Matrigel plus assay (16), was performed. In this assay, angiogenesis-inducing compounds such as bFGF are introduced into cold liquid Matrigel which, following subcutaneous injection, solidifies and permits subsequent penetration by host cells that induce vascularization. Assessment of angiogenic reactions in the Matrigel plug is achieved either by examination of plugs or by determination of the hemoglobin content. Matrigel containing bFGF (250 ng/ml) with or without delphinidin (300 mM) was s.c. injected into Crl:CD-1 Ò -nuBR nude mice and, 7 days later, the formed Matrigel plugs in mice were excised and photographed. Matrigel plugs with bFGF alone appeared red in color. In contrast, Matrigel plugs that contained no bFGF or bFGF plus delphinidin were pale in color, indicating no or less blood vessel formation ( Figure 7A ). The hemoglobin content inside the Matrigel plugs was measured to quantify the inhibition of angiogenesis induced by delphinidin. Delphinidin significantly inhibited the hemoglobin quantity (to $1.6 mg/ml) compared with the bFGF control ($3.7 mg/ml) ( Figure 7B ), indicating that delphinidin is capable of inhibiting angiogenesis formation in vivo.
Discussion
Anthocyanidins, aglycons of anthocyanins, are abundant in fruits and vegetables, and make a major contribution to the total polyphenol dietary intake (25) . They have been associated with a broad spectrum of beneficial health effects ranging from the treatment of diabetic retinopathy (26) , atherosclerosis (27) and various microvascular diseases to potential antiinflammatory (28), antitumoral (29) , antimutagenic and anticarcinogenic (30) , and chemoprotective properties (31) . Only a few studies have described the antiangiogenic activities of anthocyanidins (32) (33) (34) (35) (36) (37) (38) . One study reported that delphinidin induces a downregulation of cyclin A and D1 expression and an upregulation of p27 kip1 expression in HUVEC (36) . These two proteins are essential for cell-cycle progression, and these changes in their expression resulted in the inhibition of VEGF-induced HUVEC migration and proliferation, and in the inhibition of neovascularization of developing embryo in the chick chorioallantoic membrane (CAM) assay (36) . Here, we demonstrate for the first time that the inhibitory effect of delphinidin on angiogenesis may involve its effect on the predominant VEGF receptor, VEGFR-2. Delphinidin inhibited VEGF-dependent tyrosine phosphorylation of VEGFR-2 in a dose-and time-dependent manner and this inhibitory effect is associated with the inhibition of the downstream signaling pathways triggered by the receptor, such as the ERK-1/2 pathway in HUVEC. The inhibitory effect of delphinidin on these processes resulted in the inhibition of two key events underlying angiogenesis, i.e. EC migration and morphogenic differentiation into capillary-like structures, in both in vitro and in vivo models.
VEGF is a strong activator of ERK-1/2 via VEGFR-2 and the assumption that this pathway plays a central role in angiogenesis is supported by the finding that specific inhibitors of MEK-1/2 (mitogen-activated protein kinase/ERK Fig. 2 . Effect of delphinidin on VEGF-induced tube formation of HUVEC in 3D fibrin gels. HUVECs were cultured within fibrin gels in serum-free medium containing (or lacking) delphinidin (25 mM) and stimulated with VEGF (75 ng/ml) as described in Materials and methods. After 6 h, cells were photographed (Â100). The pictures shown are representative of three independent experiments. Delphinidin inhibits VEGFR-2 phosphorylation kinase 1/2), the kinase responsible for ERK-1/2 activation, reduce EC tubulogenesis in vitro (39) . Furthermore, ERK-1/2 plays an important role in regulating cell motility (40) . Therefore, the inhibition of VEGF-induced EC migration by delphinidin may be related to its inhibitory action on VEGFR-2 activity, resulting in the inhibition of ERK-1/2. We observed that delphinidin also potently inhibited capillary-like structure formation by HUVEC embedded in 3D fibrin gels in response to VEGF. Moreover, delphinidin remarkably suppressed induction of new blood vessel formation ($66%), in Matrigel plugs implanted in mice, in response to bFGF. Although, in this model, bFGF is a stronger inducer of new blood vessels than is VEGF (data not shown), an intimate cross-talk exists among bFGF and VEGF during angiogenesis. Several experimental evidences point to the possibility that bFGF induces neovascularization indirectly by the activation of the VEGF/ VEGFR system. Indeed, it has been shown that the quiescent endothelium of vessels of mouse cornea express both VEGF mRNA and protein only after bFGF treatment, and systemic administration of anti-VEGF neutralizing antibodies dramatically reduces bFGF-induced vascularization (41) . Thus, bFGF requires the activation of the VEGF/VEGFR system for promoting angiogenesis and conversely, VEGF may require bFGF for exerting its angiogenic potential. Since the formation of neovessels by angiogenesis in vivo is a very complex process involving the interplay of several cytokines and their receptors, it is possible that the antiangiogenic activities of delphinidin observed in our in vivo Matrigel plug assay (which already contains several endogenous angiogenic factors including VEGF and bFGF) may be related to its inhibitory effect on VEGFR-2 activity via bFGF and VEGF actions. The fact that the potent inhibitory effect of delphinidin on neovascularization has also been demonstrated in the CAM model, in which VEGF receptors are expressed and VEGF is endogenously produced (36) , strongly supports the concept that in vivo, delphinidin may be a potent angiogenesis inhibitor. Delphinidin is found in high amounts in berries as compared to other fruits (42) . Lowbush 'wild' blueberries (Vaccinium angustifolium) are one of the richest fruit sources of anthocyanins (43) and exhibit one of the highest hydrophilic ORAC FL (oxygen radical absorbance capacity fluorescein) values for fruits tested so far (44) . The possible health benefits of anthocyanins in preventing chronic and degradative diseases such as heart disease and cancer have been partly attributed to their antioxidant capacity (12, 25) . However, since the other anthocyanidins tested in this work have an antioxidant capacity very similar to that of delphinidin but did not inhibit tube formation by HUVEC, the existence of additional mechanisms responsible for the inhibitory effect of delphinidin on VEGFR-2 is likely. Although the mechanisms by which delphinidin elicits this inhibitory effect is not yet known, structure-function analysis suggests that the inhibitory effects of delphinidin were enhanced by the presence of three hydroxyl groups at the B-ring as compared to other anthocyanidins (Table I) . Furthermore, a free hydroxyl group at Position 3 also seems to be essential for potent inhibition since the presence of sugar residues at this position in delphinidin 3-O-beta-glucopyranoside eliminated the inhibitory properties of delphinidin. Thus, delphinidin, a compound with four hydroxyl groups (3, 3 0 , 4 0 and 5 0 ), clearly exhibited the highest inhibitory potency. Besides VEGFR-2, the presence of vicinal hydroxyl substituents on the B-ring of delphinidin also seems to be crucial for interaction with another tyrosine kinase receptor, EGFR (epidermal growth factor receptor) in the human vulva carcinoma cell line A431 (45, 46) . This observation suggests that the tyrosine kinase activity associated with these two cell surface receptors is indeed inhibited by delphinidin. Thus, this molecule seems to act as a multifunctional anticancer agent through its inhibitory effect on several aspects of both tumor growth and tumor angiogenesis. Depending on nutrition customs, the daily intake of anthocyans (i.e. anthocyanins and anthocyanidins) in humans is estimated to be a few hundred milligrams per day (47) . They are absorbed from the stomach (48) and intestinal cells (49) and are rapidly detected in plasma in vivo (50), suggesting that they are bioavailable to exert their biological effects. Studies of the pharmacokinetics of these compounds after their consumption as single agents, anthocyans mixtures or berry extracts suggest that anthocyans reach levels of 10 À8 -10 À7 M in human blood (51) . In our study, we observed that low concentrations of delphinidin were sufficient to significantly inhibit VEGFR-2 activity. Indeed, a 50% inhibition of VEGF-dependent tyrosine phosphorylation of VEGFR-2 could be observed at a concentration of 2 mM delphinidin. It is thus tempting to speculate that the inclusion of berries in the diet may have chemopreventive effects through the inhibition of angiogenesis.
In conclusion, this study provides the first evidence that VEGF stimulation of the tyrosine phosphorylation of VEGFR-2 is inhibited in a dose-and time-dependent manner by one of the most abundant anthocyanidins, delphinidin. We have shown recently that a number of dietary-derived polyphenols, including the green tea catechin EGCG and ellagic acid, a phenolic acid present in some fruits and nuts (9, 11) , act as potent VEGFR inhibitors, suggesting that efficient pharmacological impairment of this important signaling cascade can be achieved by dietary intervention strategies (52) . The observation that delphinidin also acts as a potent inhibitor of VEGFR-2, shutting off downstream signaling cascades crucial for EC tube formation, further support this hypothesis and highlights the potency of dietary-derived polyphenols as crucial determinants of the chemopreventive properties of fruits and vegetables.
